Joseph Michael Fitzgerald - Jan 1, 2025 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Role
EVP & Group Pres, Cardiology
Signature
/s/ Susan Thompson, Attorney-in-Fact
Stock symbol
BSX
Transactions as of
Jan 1, 2025
Transactions value $
-$573,881
Form type
4
Date filed
1/3/2025, 04:32 PM
Previous filing
Feb 13, 2025
Next filing
Feb 14, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BSX Common Stock Options Exercise $0 +13.9K +9.39% $0.00 162K Jan 1, 2025 Direct F1
transaction BSX Common Stock Tax liability -$574K -6.43K -3.97% $89.32 156K Jan 1, 2025 Direct
holding BSX Common Stock 4.89K Jan 1, 2025 By Child F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BSX Performance Share Units Options Exercise $0 -13.9K -100% $0.00 0 Jan 1, 2025 Common Stock 13.9K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.
F2 The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose.
F3 Each performance shares unit represents the Company's commitment to issue one share of Boston Scientific common stock.